NK:IO, a leader in natural killer (NK) cell biology applied to the development of exceptionally potent, off-the-shelf cell therapies targeting solid tumours, has raised £1.2m. The latest investment has swelled the company’s total equity financing to £3.2m and is in addition to £1.9m grants. The £1.9m comprises the recent Innovate UK New Cancer Therapeutics award … Continue reading NK:IO raises £1.2m to fund cancer testing